Hers and Semaglutide: The Molecule and the 503A Pathway

Part of the PlexusDx Education Hub, our library of evidence-led guidance on GLP-1 therapies, weight-management protocols, and the genetics that shape metabolic care. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Hers, receives no affiliate compensation, and gains nothing from how you act on this article.

Semaglutide is a single molecule that reaches patients under several names and through more than one supply route. This review looks specifically at how a Hers telehealth program handles semaglutide, from the intake screen to the pharmacy that fills the order, and closes with the biological context a prescription alone leaves out. Editorial balance, not a buying nudge. As of April 2026.

Semaglutide, the molecule behind the brand names

Semaglutide is a GLP-1 receptor agonist, a class that mimics an incretin hormone involved in appetite signaling and glucose handling. It circulates commercially as FDA-approved branded products and, separately, as compounded preparations. A telehealth program describing "semaglutide" is not naming a single product but a molecule that can arrive by different routes, which is why the dispensing pathway is worth reading closely before you commit.

The Hers telehealth model at a glance

Hers (Hims & Hers Health) is a subscription telehealth service. Its GLP-1 workflow generally involves a virtual clinical evaluation by a licensed provider, a written prescription directed either to a retail pharmacy for an FDA-approved brand or to a 503A compounding pharmacy for a compounded formulation, and continued follow-up. You can review the current program structure and any published pricing on Hers's official website.

The 503A compounding pathway explained

A 503A compounding pharmacy prepares medications for individual patients under a prescription. Compounded semaglutide produced through that channel is not itself an FDA-approved product, a point that separates it from a branded pen. Programs that lean on compounding do so within that regulatory frame, and the specifics of preparation, concentration, and labeling belong to the dispensing pharmacy rather than to the telehealth brand.

The evidence base for semaglutide

Semaglutide's weight-management data comes largely from the STEP program, published in The New England Journal of Medicine in 2021. The broader class includes liraglutide and dulaglutide as GLP-1 receptor agonists and tirzepatide as a GIP/GLP-1 dual agonist, the latter studied in SURMOUNT (NEJM, 2022) and SURMOUNT-OSA (NEJM, 2024). Endpoints and populations differ across these trials, and results are individual.

The genetic layer these programs leave out

A semaglutide prescription does not account for the upstream genetic architecture that shapes how any GLP-1 compound behaves in a given body. Variants in FTO, the fat-mass and obesity-associated gene, along with GLP1R (the GLP-1 receptor gene that every GLP-1 compound targets), MC4R (a melanocortin receptor tied to satiety and energy balance), and TCF7L2 (a transcription factor linked to glucose homeostasis) describe the metabolic terrain a clinician is prescribing into. These are pathway-level signals. They do not predict response to any specific medication, but they map the biology beneath the decision, context a telehealth prescription on its own never captures.

PlexusDx provides semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What distinguishes the approach is that upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including FTO, GLP1R, MC4R, and TCF7L2 variants that shape baseline appetite-regulation and energy-balance biology. Pairing that profile with the protocol is the test before you invest approach, turning guesswork into an informed conversation with your healthcare provider.

Not affiliated: PlexusDx is not affiliated with Hers and holds no commercial relationship with the companies discussed in this article.

Related reading on PlexusDx: Wegovy Com Coupon, Wegovy Price Without Insurance, Generic Wegovy, Coupons For Wegovy.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols, and this review compares approaches within the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: explore the Weight Management Protocols for semaglutide and tirzepatide paired with the genetic context most telehealth programs omit. Or begin upstream and take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions

What is semaglutide?

Semaglutide is a GLP-1 receptor agonist, a molecule that mimics an incretin hormone involved in appetite and glucose regulation. It reaches patients as FDA-approved branded products and, separately, as compounded preparations, so "semaglutide" names a molecule rather than a single finished product.

What does the 503A pathway mean for semaglutide?

A 503A compounding pharmacy prepares medication for an individual patient under a prescription. Compounded semaglutide made this way is not itself an FDA-approved product, which distinguishes it from a branded pen. Preparation and labeling specifics belong to the dispensing pharmacy rather than the telehealth brand.

Can the genetic test tell me my semaglutide dose?

No. The Precision Peptide Genetic Test does not set doses or predict drug response. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that describe baseline GLP-1 biology, giving you and your provider upstream context rather than a prescription recommendation.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education